Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: Cohort profile

Research output: Contribution to journalArticle

Abstract

Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.

Original languageEnglish (US)
Article numbere032707
JournalBMJ open
Volume9
Issue number11
DOIs
StatePublished - Nov 1 2019

Fingerprint

Case-Control Studies
Electronic Health Records
Research
Epidemiologic Studies
Cohort Studies
Genotype
Control Groups
Population
Clinical Studies

Keywords

  • cohort
  • electronic health records
  • mayo clinic biobank

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{4308a7e42d744491a02d49532d7a0656,
title = "Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA: Cohort profile",
abstract = "Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21{\%} response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77{\%}, n=43 836), Jacksonville, Florida (18{\%}, n=10 368) and La Crosse, Wisconsin (5{\%}, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43{\%} of participants were 65 years of age or older and female participants were more frequent (59{\%}) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90{\%} white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.",
keywords = "cohort, electronic health records, mayo clinic biobank",
author = "Olson, {Janet E.} and Euijung Ryu and Hathcock, {Matthew A.} and Ruchi Gupta and Bublitz, {Joshua T.} and Takahashi, {Paul Y.} and Bielinski, {Suzette J.} and {St Sauver}, {Jennifer L.} and Karen Meagher and Sharp, {Richard R.} and Thibodeau, {Stephen N.} and Mine Cicek and Cerhan, {James R.}",
year = "2019",
month = "11",
day = "1",
doi = "10.1136/bmjopen-2019-032707",
language = "English (US)",
volume = "9",
journal = "BMJ Open",
issn = "2044-6055",
publisher = "BMJ Publishing Group",
number = "11",

}

TY - JOUR

T1 - Characteristics and utilisation of the Mayo Clinic Biobank, a clinic-based prospective collection in the USA

T2 - Cohort profile

AU - Olson, Janet E.

AU - Ryu, Euijung

AU - Hathcock, Matthew A.

AU - Gupta, Ruchi

AU - Bublitz, Joshua T.

AU - Takahashi, Paul Y.

AU - Bielinski, Suzette J.

AU - St Sauver, Jennifer L.

AU - Meagher, Karen

AU - Sharp, Richard R.

AU - Thibodeau, Stephen N.

AU - Cicek, Mine

AU - Cerhan, James R.

PY - 2019/11/1

Y1 - 2019/11/1

N2 - Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.

AB - Purpose The Mayo Clinic Biobank was established to provide a large group of patients from which comparison groups (ie, controls) could be selected for case-control studies, to create a prospective cohort with sufficient power for common outcomes and to support electronic health record (EHR) studies. Participants A total of 56 862 participants enrolled (21% response rate) into the Mayo Clinic Biobank from Rochester, Minnesota (77%, n=43 836), Jacksonville, Florida (18%, n=10 368) and La Crosse, Wisconsin (5%, n=2658). Participants were all Mayo Clinic patients, 18 years of age or older and US residents. Findings to date Overall, 43% of participants were 65 years of age or older and female participants were more frequent (59%) than males at all sites. Most participants resided in the Upper Midwest regions of the USA (Minnesota, Iowa, Illinois or Wisconsin), Florida or Georgia. Self-reported race among Biobank participants was 90% white. Here we provide examples of the types of studies that have successfully utilised the resource, including (1) investigations of the population itself, (2) provision of controls for case-control studies, (3) genotype-driven research, (4) EHR-based research and (5) prospective recruitment to other studies. Over 270 projects have been approved to date to access Biobank data and/or samples; over 200 000 sample aliquots have been approved for distribution. Future plans The data and samples in the Mayo Clinic Biobank can be used for various types of epidemiological and clinical studies, especially in the setting of case-control studies for which the Biobank samples serve as control samples. We are planning cohort studies with additional follow-up and acquisition of genetic information on a large scale.

KW - cohort

KW - electronic health records

KW - mayo clinic biobank

UR - http://www.scopus.com/inward/record.url?scp=85074716109&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85074716109&partnerID=8YFLogxK

U2 - 10.1136/bmjopen-2019-032707

DO - 10.1136/bmjopen-2019-032707

M3 - Article

C2 - 31699749

AN - SCOPUS:85074716109

VL - 9

JO - BMJ Open

JF - BMJ Open

SN - 2044-6055

IS - 11

M1 - e032707

ER -